Retracted: Dual targeting of RANKL and PD ‐1 with a bispecific antibody improves anti‐tumor immunity

Objectives The addition of RANKL / RANK blockade to immune checkpoint inhibitors ( ICI s) such as anti‐PD‐1/PD‐L1 and anti‐CTLA4 antibodies is associated with increased anti‐tumor immunity in mice. Recent retrospective clinical studies in patients with advanced melanoma and lung cancer suggest the addition of anti‐ RANKL antibody to ICI increases the overall response rate relative to ICI treatment alone. Based on this rationale, we developed a novel bispecific antibody (BsAb) co‐targeting RANKL and PD ‐1. Methods We characterized target binding and functional activity of the anti‐ RANKL / PD ‐1 BsAb in cell‐based assays. Anti‐tumor activity was confirmed in experimental lung metastasis models and in mice with established subcutaneously transplanted tumors. Results The anti‐RANKL/PD‐1 BsAb retained binding to both RANKL and PD ‐1 and blocked the interaction with respective counter‐structures RANK and PD ‐L1. The inhibitory effect of anti‐ RANKL /PD‐1 BsAb was confirmed by demonstrating a complete block of RANKL ‐dependent osteoclast formation. Monotherapy activity of anti‐ RANKL /PD‐1 BsAb was observed in anti‐PD‐1 resistant tumors and, when combined with anti‐CTLA‐4 mAb, increased anti‐tumor responses. An equivalent or superior anti‐tumor response was observed with the anti‐RANKL/PD‐1 BsAb compared with the combination of parental anti‐RANKL plus anti‐PD‐1 antibodies depending upon the tumor model. Discussion Mechanistically, the anti‐tumor activity of anti‐ RANKL / PD ‐1 BsAb required CD8 + T cells, host PD‐1 and IFNγ. Targeting RANKL and PD‐1 simultaneously within the tumor microenvironment (TME) improved anti‐tumor efficacy compared with combination of two separate mAbs. Conclusion In summary, the bispecific anti‐ RANKL / PD ‐1 antibody demonstrates potent tumor growth inhibition in settings of ICI resistance and represents a novel modality for clinical development in advanced cancer.